Reviewing AleAnna (NASDAQ:ANNA) & Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals (NASDAQ:CPRX) and AleAnna (NASDAQ:ANNA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends.

Valuation & Earnings

This table compares Catalyst Pharmaceuticals and AleAnna”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$588.99 million	5.03	$214.33 million	$1.69	14.34
AleAnna	$1.42 million	191.97	-$12.34 million	$0.04	102.25

Catalyst Pharmaceuticals has higher revenue and earnings than AleAnna. Catalyst Pharmaceuticals is trading at a lower price-to-earnings ratio than AleAnna, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Catalyst Pharmaceuticals and AleAnna’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	36.39%	36.47%	31.85%
AleAnna	-46.01%	-14.90%	-8.74%

Risk & Volatility

Catalyst Pharmaceuticals has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, AleAnna has a beta of -0.02, meaning that its share price is 102% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Catalyst Pharmaceuticals and AleAnna, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0	0	3	2	3.40
AleAnna	1	0	0	0	1.00

Catalyst Pharmaceuticals currently has a consensus price target of $34.00, indicating a potential upside of 40.26%. Given Catalyst Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe Catalyst Pharmaceuticals is more favorable than AleAnna.

Insider and Institutional Ownership

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 38.1% of AleAnna shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by company insiders. Comparatively, 42.9% of AleAnna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Catalyst Pharmaceuticals beats AleAnna on 12 of the 15 factors compared between the two stocks.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

About AleAnna

AleAnna, Inc. engages in oil and gas exploration and production activities. It focuses on Italy’s natural gas reserves and developing renewable energy solutions. The company was founded in 2007 and is headquartered in Dallas, TX.